一种高度膨胀的水凝,封装了Ginsenoside Rh4用于肥胖调节
Yanan Liu1, Haixia Yang2, Daidi Fan1
1Shaanxi Key Laboratory of Degradable Biomedical Materials, Shaanxi R&D Center of Biomaterials and Fermentation Engineering, Biotech & Biomed Research Institute, School of Chemical Engineering, Northwest University, Xi'an 710069, China.
Food research international (Ottawa, Ont.)
|August 12, 2025
概括
这项研究开发了一种新的可食用水凝,使用碳甲基纤维素和乳清蛋白来控制肥胖. 水凝有效地输送了人参化物Rh4,减少了炎症并调节了控制体重的肠道细菌.
科学领域:
- 生物材料科学 生物材料科学
- 营养科学 营养科学
- 药理学 药理学是指药理学的学科.
背景情况:
- 饮食干预对于安全的肥胖管理至关重要.
- 来自天然聚合物的可食用水凝为体重控制提供了潜力.
- 金色化物Rh4表现出与肥胖相关的低血糖和抗炎性质.
研究的目的:
- 开发一种高度膨胀的可食用水凝,封装金氏化物Rh4用于肥胖的调节.
- 评估开发的水凝的物理,化学和生物特性.
- 评估水凝在持续药物释放,生物相容性,炎症缓解和肠道微生物群调节方面的有效性.
主要方法:
- 使用碳氧甲基纤维素 (CMC) 和乳清蛋白分离物 (WPI) 制造可食用水凝.
- 液凝性质的表征,包括机械强度和膨胀率.
- 在体外和体内研究评估药物释放动力学,生物相容性,抗炎作用和对肠道菌群的影响.
主要成果:
- 该CMC-WPI水凝表现出良好的机械性能和高膨胀率.
- 优化的水凝配方证明了长期释放的金氏化物Rh4.
- 在体外和体内研究证实了优越的生物相容性,显著缓解肥胖引起的炎症,以及肠道菌群的积极调节.
结论:
- 开发的可食用水凝是一种有希望的,稳定的,易于准备的临床肥胖管理系统.
- 水凝有效地为与肥胖相关的炎症和肠道失生症提供治疗剂.
- 这种创新的生物材料有可能促进肥胖治疗中的饮食干预措施.
相关概念视频
01:24Glucagon-like Receptor Agonists
418
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
418
01:23Dipeptidyl Peptidase 4 Inhibitors
257
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
257